Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 10/20 | 0.59 |
| ▸ | EGFR | P00533 | 4/20 | 0.52 |
| ▸ | CSF1R | P07333 | 3/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.46 |
| ▸ | GCGR | P47871 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1899495 | 0.85 | EGFR (0.55) | KITEGFRCSF1R | |
| SCHEMBL31565345 | 0.84 | KIT (0.61) | KITEGFRCSF1R | |
| SCHEMBL22195118 | 0.84 | KIT (0.61) | KITEGFRCSF1R | |
| SCHEMBL27414010 | 0.83 | EGFR (0.52) | KITEGFRCSF1R | |
| SCHEMBL20493380 | 0.83 | KIT (0.70) | KITEGFR | |
| SCHEMBL6259087 | 0.83 | EGFR (0.53) | KITEGFRCSF1RGCGRMAPK14 | |
| SCHEMBL16546224 | 0.83 | EGFR (0.51) | KITEGFRCSF1RBRAFTNNI3K | |
| SCHEMBL13737573 | 0.82 | KIT (0.61) | KITEGFRCSF1RBRAFTNNI3K | |
| SCHEMBL3982349 | 0.81 | KIT (0.59) | KITEGFRCSF1RBRAFTNNI3K | |
| SCHEMBL4899896 | 0.79 | EGFR (0.57) | KITEGFRCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | WYETH (US) | 2009-05-07 | — | — | US | disclosed |
| WO-2009059272-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | WYETH (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | BRAF, ARAF, RAF1 | KIT 1616/4885EGFR 1346/4885CSF1R 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.